Precision BioSciences, Inc. DTIL
9.50 USD -0.18 (-1.86%)
At closeNov 10, 2026, 4:01 PM EST
9.50 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
9.22 Day range 10.02
3.53 52-week range 11.29
- YTD
- +128.37%
- 1 year
- +56.51%
News
seekingalpha.com Precision BioSciences, Inc. (DTIL) Discusses Phase 1 ELIMINATE-B Data for PBGENE-HBV in Chronic Hepatitis B Transcript Precision BioSciences, Inc. ( DTIL ) Discusses Phase 1 ELIMINATE-B Data for PBGENE-HBV in Chronic Hepatitis B November 9, 2026 8:00 AM EST Company Participants Naresh Tanna - Chief Financial Officer…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of…
businesswire.com Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
businesswire.com Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
businesswire.com Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
benzinga.com UPDATE: Precision BioSciences Q3 Adj. EPS $(0.74) Beats $(0.85) Estimate Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.85) by 12.94 percent. This is a 59.78 percent increase over losses…
benzinga.com Precision BioSciences Q3 EPS $(0.28) Beats $(0.85) Estimate Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.85) by 67.06 percent. This is a 84.78 percent increase over losses…
businesswire.com Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
businesswire.com Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026 DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
defenseworld.net Precision BioSciences (NASDAQ:DTIL) Stock Price Breaks Below 200 Day Moving Average – Time to Sell? Precision BioSciences, Inc. (NASDAQ: DTIL - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of…
businesswire.com Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026 DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…- benzinga.com iECURE Says Updated OTC-HOPE Low-Dose Data Showed 74% Reduction In Annualized Hyperammonemic Crises, 57% Reduction In Hyperammonemic Events; Completes Phase 1/2 Dosing Across All Three Cohorts iECURE, a private clinical-stage genome editing company, reported preliminary safety observations from all nine participants dosed with ECUR-506 across the low-, intermediate- and high-dose cohorts,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 35.9% to $7.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.2 million. Biodexa…- benzinga.com Precision BioSciences Doses First Patient In The Phase 1/2 Function-DMD Clinical Trial Evaluating PBGENE-DMD For Treatment Of Duchenne Muscular Dystrophy PBGENE-DMD is Precision's wholly owned in vivo gene editing program designed to durably improve function. This novel approach, aiming to restore near full-length dystrophin, is applicable for up to…
businesswire.com Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
seekingalpha.com Precision BioSciences: Promising HBV Editing Evidence PBGENE-HBV's liver biopsy data provides unusually direct evidence that ARCUS is editing the viral reservoir in patients. Durable off-treatment viral control remains unproven, making the next…
gurufocus.com Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene editi
businesswire.com Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
benzinga.com HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60 price target.
businesswire.com Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026 DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…- benzinga.com Precision BioSciences Promotes Alex Kelly To COO And Naresh Tanna To CFO, Effective August 1, 2026 – Leadership updates come as Precision advances its lead programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy –Precision BioSciences, Inc. (NASDAQ:DTIL), a…
businesswire.com Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
businesswire.com Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
benzinga.com HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60 price target.
zacks.com Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength? Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further…
benzinga.com Precision Biosciences Activates Second Clinical Site At Washington University School Of Medicine As It Begins The FUNCTION-DMD Clinical Trial Evaluating PBGENE-DMD For Duchenne Muscular Dystrophy; Initial Safety Data Targeted For End-2026 Also in its updated corporate deck, the Company announced activation of a second clinical site at Washington University School of Medicine in St. Louis, Missouri as it commences the FUNCTION-DMD…
gurufocus.com Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene edit
businesswire.com Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…- benzinga.com Oppenheimer Initiates Coverage On Precision BioSciences with Outperform Rating, Announces Price Target of $20 Oppenheimer analyst Joseph Thome initiates coverage on Precision BioSciences (NASDAQ:DTIL) with a Outperform rating and announces Price Target of $20.
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60 price target.
benzinga.com Why Is Precision BioSciences Stock Gaining Wednesday? Precision BioSciences (DTIL) trades up 10.55% premarket. Bullish moving averages and new data point to strong momentum.- benzinga.com Precision BioSciences Reports PBGENE-HBV Achieves 100% pgRNA Loss And 10-Fold cccDNA Transcript Reduction In ELIMINATE-B Study - New biopsy data demonstrate thatPBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -- In the <1% of cccDNA…
gurufocus.com Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene edit
businesswire.com Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
benzinga.com Precision BioSciences Announces Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need…
benzinga.com Precision BioSciences Announces New Preclinical Data From PBGENE-DMD Program In Oral Presentation At ASGCT 2026 Annual Meeting – New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to…- benzinga.com Precision BioSciences Q1 EPS $(0.75) Misses $(0.66) Estimate, Sales $10.838M Beat $4.050M Estimate Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.66) by 15.38 percent. This is a 66.06 percent increase over…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Precision Biosciences Starts Phase 1/2 FUNCTION-DMD Study Of PBGENE-DMD, In Vivo Gene Editing Treatment For Duchenne Muscular Dystrophy Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need…
benzinga.com iECURE To Present Clinical Data From Ongoing ECUR-506 Trial Using Precision Bioscience's ARCUS Nuclease At American Society Of Gene & Cell Therapy Annual Meeting May 11-15 iECURE has licensed the ARCUS® nuclease from Precision BioSciences for four gene insertion programs including OTC, CTLN1 and PKU.The poster presentation at SIMD will feature one-year post-treatment…- benzinga.com Jones Trading Assumes Precision BioSciences at Buy, Announces Price Target of $30 Jones Trading analyst Catherine Novack assumes Precision BioSciences (NASDAQ:DTIL) with a Buy rating and announces Price Target of $30.
- benzinga.com Precision BioSciences Receives Clinical Trial Application Approval To Expand Ongoing Global ELIMINATE-B Clinical Trial Of PBGENE-HBV - France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment -Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company…
- benzinga.com Earnings Scheduled For March 12, 2026
- benzinga.com Precision BioSciences Receives Two Notices Of Allowance From USPTO For Patent Applications Relating To PBGENE-HBV Program Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need…
- benzinga.com Precision BioSciences Says FDA Grants Fast Track Designation To PBGENE-DMD For Treatment Of Duchenne Muscular Dystrophy – Fast Track designation aims to facilitate development and expedite review of drugs, such as PBGENE-DMD to treat serious conditions like Duchenne muscular dystrophy –– March 17, 2026 virtual webinar…
- benzinga.com Precision BioSciences Lands $7.5M Milestone Payment From TG Therapeutics In MS Drug Trial Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need…
- benzinga.com Precision BioSciences Receives Study May Proceed Notification From FDA, Allowing Co To Initiate IRB Activities And Clinical Trial Site Activation For FUNCTION-DMD Phase 1/2 Clinical Trial For PBGENE-DMD – U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne muscular dystrophy (DMD) ––…
- benzinga.com Precision BioSciences Provides 2026 Business Update Emphasizing Progress In PBGENE-HBV And PBGENE-DMD Programs, Anticipated Clinical Data In 2026, And Strong $137M Cash Runway Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences in 2026PBGENE-DMD expecting IND clearance in Q1 2026 for Phase 1/2…
- benzinga.com Precision Biosciences Advances Gene Therapy Pipeline With Ongoing Phase 1/2a ELIMINATE‑B Trial For PBGENE‑HBV And Anticipated Q1 2026 IND Clearance For PBGENE‑DMD; Data Updates Expected Throughout 2026 Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences in 2026PBGENE-DMD expecting IND clearance in Q1 2026 for Phase 1/2…